

Hemp for Health Inc.

Condensed Interim Consolidated Financial Statements

For the six months ended October 31, 2019

HEMP FOR HEALTH INC.
CONDENSED INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION
(Stated in Canadian Dollars)

As at	October 31, 2019	April 30, 2019
Assets		
Current		
Cash	\$ 462,183	\$ 1,551,062
Short-term investments (note 3)	401,995	-
Taxes receivable (note 4)	188,721	13,954
Crop cost advances (note 4)	-	388,527
Prepaid expenses and advances	224,871	218,950
Total Current Assets	1,277,770	2,172,493
Non-Current assets		
Fixed assets	8,758	-
Total Assets	\$ 1,286,528	\$ 2,172,493
Liabilities		
Current		
Trade and Other Payables	\$ 70,074	\$ 31,277
Equity		
Share capital (note 5)	\$ 2,539,900	\$ 2,310,660
Special warrants (note 5)	78,400	-
Reserves (note 5)	72,140	67,140
Accumulated deficit	(1,473,986)	(236,584)
Total Equity	1,216,454	2,141,216
Total Liabilities and Equity	\$ 1,286,528	\$ 2,172,493

Basis of preparation and going concern (note 2)
Subsequent events (notes 3 and 5)

APPROVED ON BEHALF OF THE DIRECTORS:

“Robert Eadie”
Robert Eadie, Director

“Gary Arca”
Gary Arca, Director

The accompanying notes form an integral part of these consolidated financial statements

HEMP FOR HEALTH INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE LOSS
(Stated in Canadian Dollars)

	For the three months ended October 31,		For the six months ended October 31,	
	2019	2018	2019	2018
Expenses:				
Audit and consulting fees (note 9)	\$ 55,271	\$ -	\$ 122,691	\$ -
Foreign exchange loss (gain)	(4,197)	-	16,056	-
Legal and corporate services (note 9)	78,541	-	78,541	-
Marketing	13,879	-	20,422	-
Office, rent and administration (note 9)	30,949	-	59,973	-
Research and development (note 4)	377,389	-	795,507	-
Shareholder communication	269	-	4,154	-
Transfer agent and filing fees	11,100	-	24,934	-
Travel and accommodations	47,041	-	124,444	-
Total expenses	610,242	-	1,246,722	-
Other income:				
Interest earned	(3,175)	-	(9,320)	-
Total loss and comprehensive loss for the period	\$ (607,067)	\$ -	\$ (1,237,402)	\$ -
Basic and diluted loss per share for the period	\$ (0.03)	\$ -	\$ (0.06)	\$ -
Weighted average shares outstanding – basic and diluted - Note 6	19,670,001	-	19,630,544	-

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements

HEMP FOR HEALTH INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(Stated in Canadian Dollars)

For the six months ended October 31,	2019	2018
Cash provided by		
Operating activities		
Loss for the period	\$ (1,237,402)	\$ -
Items not involving cash:		
Amortization	461	-
Interest earned	(1,995)	-
Research and development expense	388,527	-
Cash generated by operating activities before working capital changes	(850,409)	-
Change in non-cash working capital items		
Amounts receivable	(174,767)	-
Prepaid expenses and advances	(5,921)	-
Trade and other payables	38,797	-
Cash outflow for operating activities	(992,300)	-
Financing activities		
Share issuance	242,000	-
Share issuance costs	(7,760)	-
Share subscription received	78,400	-
Cash inflow for financing activities	312,640	-
Investing activities		
Purchase of short-term investments	(400,000)	-
Purchase of fixed assets	(9,219)	-
Cash outflows for investing activities	(409,219)	-
Total decrease in cash	(1,088,879)	-
Cash, beginning of period	1,551,062	-
Cash, end of period	\$ 462,183	\$ -

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements

HEMP FOR HEALTH INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Stated in Canadian Dollars)

	Number of Shares Outstanding	Share Capital	Special Warrants	Reserves	Accumulated Deficit	Total equity
Balance – October 1, 2018	1	\$ -	\$ -	\$ -	\$ -	\$ -
Balance – October 31, 2018	1	-	-	-	-	-
Common shares issued pursuant to:						
- Private placement of \$0.01	1,500,000	15,000	-	-	-	15,000
- Issued as fees at \$0.01	1,500,000	15,000	-	-	-	15,000
- Private placement of \$0.05	3,900,000	195,000	-	-	-	195,000
- Private placement of \$0.10	100,000	10,000	-	-	-	10,000
- Private placement of \$0.20	11,460,000	2,292,000	-	-	-	2,292,000
Share issuance costs	-	(216,340)	-	67,140	-	(149,200)
Loss for the year	-	-	-	-	(236,584)	(236,584)
Balance – April 30, 2019	18,460,001	2,310,660	-	67,140	(236,584)	2,141,216
Common shares issued pursuant to:						
- Private placement of \$0.20	1,210,000	242,000	-	-	-	242,000
Share issuance costs	-	(12,760)	-	5,000	-	(7,760)
Share subscription	-	-	78,400	-	-	78,400
Loss for the period	-	-	-	-	(1,237,402)	(1,237,402)
Balance – October 31, 2019	19,670,001	\$ 2,539,900	\$ 78,400	\$ 72,140	\$ (1,473,986)	\$ 1,216,454

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements

HEMP FOR HEALTH INC.
NOTES TO THE CONSENSUED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
For the six months ended October 31, 2019 and 2018
(Stated in Canadian Dollars)

Note 1 **Corporate Information**

Hemp for Health Inc. (the “Company”) was incorporated on October 1, 2018 under the *Business Corporations Act* of British Columbia as 1181427 B.C. Ltd, and then Euro Grow Ltd. on October 3, 2018. It did not commence operations until November 2, 2018. The Company changed its name again to Hemp for Health Inc. on May 3, 2019. The Company is in the business of growing, processing, packaging and selling cannabidiol and related hemp based products in Italy. The Company set up a wholly-owned Italian subsidiary, Hemp For Health H4H s.r.l. (“H4Hsrl”) that operates the business interests in Italy.

The registered address of the Company’s corporate office and principal place of business is 750 – 580 Hornby Street, Vancouver, British Columbia, Canada.

Note 2 **Basis of Preparation and Going Concern**

a) Statement of Compliance

These unaudited condensed interim consolidated financial statements for the Company have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). These unaudited condensed interim consolidated financial statements, for the period ended October 31, 2018, have been prepared in accordance with International Accounting Standard (“IAS”) 34 Interim Financial Reporting, and do not include all the information required for full annual financial statement.

These unaudited condensed interim consolidated financial statements should be read in conjunction with the Company’s April 30, 2019 audited annual financial statements.

The financial statements were authorized for issue by the Board of Directors on December 19, 2019.

b) Basis of Measurement and Going Concern

The unaudited condensed interim consolidated financial statements have been prepared on a historical cost basis, except biological assets, which are measured at fair value, as explained in the Company’s accounting policies discussed in note 3 of the Company’s April 30, 2019 audited annual financial statements.

The preparation of condensed interim consolidated financial statements in compliance with IFRS requires management to make certain critical accounting estimates. It also requires management to exercise judgement in applying the Company’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in Note 4 of the Company’s April 30, 2019 audited annual financial statements.

HEMP FOR HEALTH INC.

Notes to the Condensed Interim Consolidated Financial Statements

October 31, 2019

(Stated in Canadian Dollars) - Page 2

Note 2 Basis of Preparation and Going Concern – (cont'd)

b) Basis of Measurement and Going Concern – (cont'd)

The Company has not generated revenue from operations. The Company incurred a loss of \$1,237,402 during the period ended October 31, 2019. These conditions indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern. While the Company has been successful in obtaining the necessary financing through the issuance of common shares in the past, there is no assurance it will be able to raise funds in this manner in the future. As at October 31, 2019, the Company had \$462,183 in cash, \$401,995 in short-term investments, working capital of \$1,207,696 and no long-term debt.

These financial statements do not give effect to adjustments that would be necessary should the Company be unable to continue as a going concern and, therefore, be required to realize its assets and liquidate its liabilities and commitments in other than the normal course of operations, and at amounts different from those in the accompanying consolidated financial statements.

c) Basis of Consolidation

These condensed interim consolidated financial statements include the accounts of the Company and its subsidiary, which is controlled by the Company. Control exists when the Company has the power to govern the financial and operating policies of an entity so as to obtain benefits from the entity's activities. Subsidiaries are included in the consolidated financial results of the Company from the effective date of acquisition up to the effective date of disposal or loss of control. The Company's wholly-owned subsidiary, H4Hsrl, carries out its operations in Italy. All intra-group transactions, balances, income and expenses are eliminated, in full, on consolidation.

The condensed interim consolidated financial statements are presented in Canadian dollars ("CDN"), which is the functional currency of the Company.

Note 3 Short-term investments

At October 31, 2019, the Company held a Guaranteed Investment Certificate ("GIC") denominated in Canadian Dollars with a market value of \$401,995 (April 30, 2019 - \$Nil), earning interest income at 2% per annum and maturing on July 30, 2020. Subsequent to the period ending October 31, 2019, \$100,000 was redeemed.

These GIC's are cashable at the Company's option and are considered to be highly liquid. The Company's short-term investments are held in one financial institution and as such as the Company is exposed to the risks of only that financial institution.

HEMP FOR HEALTH INC.

Notes to the Condensed Interim Consolidated Financial Statements

October 31, 2019

(Stated in Canadian Dollars) - Page 3

Note 4 Crop advances & Research and development

During the year ended April 30, 2019, the Company engaged certain independent farmers and members of a farming co-operative in Tuscany, Italy to plant up to 100 hectares of hemp on behalf of the Company on a test basis using seeds provided by the Company.

In accordance with the terms of agreements, during the year ended April 30, 2019, the Company advanced 256,200 Euros, including VAT tax, for a total of \$388,527, to be applied against costs for the hemp planting. The co-operative agreement provides for an exclusive use of the co-operative for 5 years with a 5 year renewable term. The Company has agreed to a payment of up to 10,000 Euros per hectare planted under the co-operative agreement in the first year and market value in subsequent years.

During the period ending October 31, 2019, the above advance was spent on planting of crops and was expensed as research and development for the period ended October 31, 2019, along with seed costs and additional advances to farmers and the farming co-operative in the period of \$377,389, for a total of \$795,507 net of VAT taxes receivable.

Note 5 Share capital and Equity reserve

a) Common share issuances

The Company is authorized to issue an unlimited number of no par value common shares, issuable in series. The holders of common shares are entitled to one vote per share at meetings of the Company and to receive dividends, which may be declared from time-to-time. To date, equity financings have provided the main source of financing.

No dividends have been declared by the Company since its inception. All shares are ranked equally with regard to the Company's residual net assets.

During the period ended October 31, 2019, the Company issued the following shares:

- On May 6, 2019, the Company closed a second tranche of the financing and issued 1,210,000 units priced at \$0.20 per unit, for gross proceeds of \$242,000. Each unit consists of one common share of the Company and one-half of one share purchase warrant for 605,000 whole warrants, with each warrant entitling the holder thereof to acquire an additional common share of the Company for a period of two years at a price of \$0.30 per share.

The fair value of the shares was equal to the proceeds raised in the private placement and as a result, no amount was allocated as the fair value of the warrants. Cash payments totalling \$7,760 and 38,800 finder's warrants, with the same terms and conditions as the unit warrants, were paid as finders' fees. Share issue costs include \$5,000 calculated as the fair value of the finder's warrants. The fair value of finder's warrants was determined using the Black-Scholes model with the following assumptions:

HEMP FOR HEALTH INC.

Notes to the Condensed Interim Consolidated Financial Statements

October 31, 2019

(Stated in Canadian Dollars) - Page 4

Note 5 Share capital and Equity reserve – (cont'd)a) Common share issuances – (cont'd)

Stock price	\$0.20
Exercise price	\$0.30
Dividend rate	0%
Expected life	2 Years
Expected annual volatility	125.00%
Risk-free rate	2.14%

- In July and September, 2019, the Company issued 392,000 special warrants priced at \$0.20 per special warrant, for gross proceeds of \$78,400. Each special warrant is convertible into one unit consisting of one common share of the Company and one-half of one share purchase warrant for 196,000 whole warrants, with each warrant entitling the holder thereof to acquire an additional common share of the Company for a period of two years at a price of \$0.30 per share. Subsequent to the period ending October 31, 2019, the special warrants converted to units of common shares and share purchase warrants as the Company obtained a receipt to the final prospectus qualifying the issuance of the units. The fair value of the shares was equal to the proceeds raised in the private placement and as a result, no amount was allocated as the fair value of the warrants. No finders' fees were paid.

During the year ended April 30, 2019, the Company:

- Completed a private placement in November, 2018, for aggregate proceeds of \$15,000 through the issuance of 1,500,000 shares at \$0.01 per share.
- Issued 1,500,000 shares at a value of \$0.01 per share for fees relating to farm crops and consulting services.
- Completed private placements in December, 2018, issuing 3,900,000 shares at a price of \$0.05 per share for proceeds of \$195,000 and through the issuance of 100,000 shares at a price of \$0.10 per share for proceeds of \$10,000.
- Closed the first tranche of a private placement on April 26, 2019, issuing 11,460,000 units priced at \$0.20 per unit, for gross proceeds of \$2,292,000. Each unit consists of one common share of the Company and one-half of one share purchase warrant for 5,730,000 whole warrants, with each whole warrant entitling the holder thereof to acquire an additional common share of the Company for a period of two years at a price of \$0.30 per share.

The fair value of the shares was equal to the proceeds raised in the private placement and as a result, no amount was allocated as the fair value of the warrants. Cash payments totalling \$149,200 and 746,000 finder's warrants, with the same terms and conditions as the unit warrants, were paid as finders' fees. Share issue costs include \$67,140 calculated as the fair value of the finder's warrants.

HEMP FOR HEALTH INC.

Notes to the Condensed Interim Consolidated Financial Statements

October 31, 2019

(Stated in Canadian Dollars) - Page 5

Note 5 Share capital and Equity reserve – (cont'd)a) Common share issuances – (cont'd)

The fair value of finder's warrants was determined using the Black-Scholes model with the following assumptions:

Stock price	\$0.20
Exercise price	\$0.30
Dividend rate	0%
Expected life	2 Years
Expected annual volatility	100.00%
Risk-free rate	2.14%

b) Warrants

A summary of the Company's outstanding share purchase warrants at October 31, 2019, April 30, 2019 and October 31, 2018 is presented below:

	Number of warrants	Weighted average exercise price
Balance October 31, 2018	-	\$ -
Warrants issued	6,476,000	0.30
Balance, April 30, 2019	6,476,000	0.30
Warrants issued	643,800	0.30
Outstanding at October 31, 2019	7,119,800	\$ 0.30

A summary of the Company's outstanding share purchase warrants is presented below:

Number of Warrants	Exercise Price	Expiry Date
6,476,000	\$0.30	April 26, 2021
643,800	\$0.30	May 6, 2021
7,119,800	\$0.30	

In addition, as explained above, the Company issued 392,000 special warrants convertible into one unit consisting of one common share of the Company and one-half of one share purchase warrant for 196,000 whole warrants, with each warrant entitling the holder thereof to acquire an additional common share of the Company for a period of two years at a price of \$0.30 per share. Subsequent to the period ending October 31, 2019, the special warrants converted to units of common shares and share purchase warrants.

HEMP FOR HEALTH INC.

Notes to the Condensed Interim Consolidated Financial Statements

October 31, 2019

(Stated in Canadian Dollars) - Page 6

Note 5 Share capital and Equity reserve – (cont'd)c) Share-Based Payments

The Company's Board has adopted a Stock Option Plan available to eligible directors, officers, employees and consultants to acquire up to 10% of common shares then outstanding (the "Plan"). Under the Plan, options may be granted By the Board at an option price in accordance with regulatory policy for a maximum term of 10 years.

No amounts are paid or payable by the recipient on receipt and the options are not dependent on any performance-based criteria. Share purchase options will vest at the discretion of the Company and in accordance with regulatory policy. No share purchase options were granted during the period ended October 31, 2019.

Note 6 Loss Per Share

The denominator for the calculation of loss per share, being the weighted average number of common shares for the period ended October 31, 2019 and 2018 is as follows:

	Three months ended		Six months ended	
	October 31,		October 31,	
	2019	2018	2019	2018
Issued and outstanding, beginning of the period	19,670,001	-	18,460,001	-
Weighted average shares issued during the period	-	-	1,170,543	-
Basic and diluted weighted average number of shares	19,670,001	-	19,630,544	-

Note 7 Capital Management

The Company's objective when managing capital is to safeguard the Company's ability to continue as a going concern, so that it can continue to provide returns for shareholders and benefits for other stakeholders. The Company considers the items included in shareholders' equity as capital. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may issue new shares through private placements, sell assets to reduce debt or return capital to shareholders. The Company is not subject to externally imposed capital requirements.

Note 8 Financial Instruments

As at October 31, 2019, the Company's financial instruments consist of cash, short-term investments, amounts receivable and trade and other payables. The fair value of the Company's cash and trade and other payables approximate their carrying value, which is the amount on the statements of financial position, due to their short-term maturities or ability of prompt liquidation.

HEMP FOR HEALTH INC.

Notes to the Condensed Interim Consolidated Financial Statements

October 31, 2019

(Stated in Canadian Dollars) - Page 7

Note 8 Financial Instruments – (cont'd)

a) Interest Rate Risk

The Company's cash earns interest at a variable interest rate. Because of the nature of these financial instruments, fluctuations in market rates do not have a significant impact on estimated fair values as of October 31, 2019. Future cash flows from interest income on cash will be affected by interest rate fluctuations. Interest rate risk consists of two components, i) To the extent that payments made or received on the Company's monetary assets and liabilities are affected by changes in the prevailing market interest rates, the Company is exposed to interest rate cash flow risk; and ii) To the extent that changes in prevailing market interest rates differ from the interest rates in the Company's monetary assets and liabilities, the Company is exposed to interest rate price risk.

The Company's exposure to interest rate fluctuations is minimal.

b) Credit Risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company is exposed to credit risk with respect to its cash and short-term investments, the balance of which at October 31, 2019 is \$462,183 (April 30, 2019 – \$1,551,062) and \$401,995 (April 30, 2019 - \$Nil) respectively. As at that date, cash and short-term investments were held at a chartered Canadian financial institution and the Company does not consider the risks to be significant.

Liquidity risk arises from the excess of financial obligations over available financial assets due at any point in time. Additional cash requirements could be met with the issuance of additional share capital; however there is no assurance the Company will be able to raise funds in this manner in the future. As at October 31, 2019, the Company was holding cash and short term investments of \$462,183 (April 30, 2019 – \$1,551,062) and \$401,995 (April 30, 2019 - \$Nil) respectively.

Note 9 Related Party Transactions

The following is a summary of charges incurred by the Company with related parties for the year ended October 31, 2019 and 2018:

<u>Year ended October 31,</u>	<u>2019</u>	<u>2018</u>
Corporate services	\$ 7,500	\$ -
Consulting fees	30,000	-
Office, rent and administration	7,500	-
<u>Total</u>	<u>\$ 45,000</u>	<u>\$ -</u>

During the six months ended October 31, 2019, the Company incurred operational expenses totalling \$45,000 (October 31, 2018: \$nil) from companies controlled by directors and officers of the Company.